Certara, Inc. (NASDAQ:CERT) Position Lowered by Commerce Bank

Commerce Bank trimmed its position in Certara, Inc. (NASDAQ:CERT) by 5.2% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,719 shares of the company’s stock after selling 1,628 shares during the period. Commerce Bank’s holdings in Certara were worth $348,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CERT. Daventry Group LP grew its position in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after acquiring an additional 791,405 shares in the last quarter. Kopion Asset Management LLC acquired a new position in Certara in the third quarter worth $4,457,000. Sei Investments Co. increased its stake in Certara by 39.5% during the second quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after purchasing an additional 282,357 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after purchasing an additional 273,095 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Certara by 9.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after buying an additional 248,448 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Price Performance

NASDAQ CERT opened at $10.93 on Wednesday. The company has a 50-day moving average price of $10.80 and a two-hundred day moving average price of $13.09. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -54.65, a price-to-earnings-growth ratio of 5.24 and a beta of 1.51. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.06 EPS. Analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

CERT has been the subject of a number of recent research reports. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Robert W. Baird lowered their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Finally, Barclays dropped their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Certara presently has an average rating of “Hold” and an average target price of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.